# Biotech Daily Digest — 2025-09-20

**11 items from 2 sources**

## Summary by Source

- Endpoints News: 5 items
- Fierce Biotech: 6 items


## Endpoints News

- **[This year’s Endpoints 11 winners; Monarez testifies to Congress; Eli Lilly’s obesity pill lags; and more](https://endpoints.news/this-years-endpoints-11-winners-monarez-testifies-to-congress-eli-lillys-obesity-pill-lags-and-more/)**  
  _Sat, 20 Sep 2025 10:00:58 +0000_  
  Welcome back to Endpoints Weekly! This week, our team gathered in Boston to honor 11 of the most promising biotech startups of 2025. Be sure to check out this year’s list of companies chasing bold ...

- **[MapLight prepares for IPO to back schizophrenia, Alzheimer's drug](https://endpoints.news/maplight-prepares-for-ipo-to-back-schizophrenia-alzheimers-drug/)**  
  _Fri, 19 Sep 2025 22:49:30 +0000_  
  MapLight Therapeutics filed for an initial public offering on Friday evening, a week after a biotech that's also working on schizophrenia treatments, LB Pharmaceuticals, notched the industry's

- **[Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug](https://endpoints.news/merck-wins-approval-of-subcutaneous-keytruda-in-bid-to-extend-life-of-worlds-top-selling-drug/)**  
  _Fri, 19 Sep 2025 18:24:36 +0000_  
  The FDA on Friday approved a new, subcutaneous formulation of the cancer drug Keytruda, which is expected to help Merck stave off some biosimilar competition in the years to ...

- **[Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma study](https://endpoints.news/regenerons-lynozyfic-yields-100-response-rate-in-small-smoldering-multiple-myeloma-study/)**  
  _Fri, 19 Sep 2025 17:15:16 +0000_  
  Regeneron reported efficacious early results on its T cell engager Lynozyfic in smoldering multiple myeloma, a precancerous condition that can turn into active multiple myeloma. The study is part of a bid to expand the ...

- **[CHMP recommends Novo's weekly diabetes injection, Bayer's menopause drug](https://endpoints.news/chmp-recommends-novos-weekly-diabetes-injection-bayers-menopause-drug/)**  
  _Fri, 19 Sep 2025 15:03:25 +0000_  
  The European Medicines Agency’s human medicines committee (CHMP) has recommended the approval of Novo Nordisk’s weekly diabetes injection that combines its insulin icodec and the GLP-1 drug semaglutide. Bayer's menopause medication and two other therapies ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/pharma/fda-greenlights-stealth-bios-injection-1st-treatment-barth-syndrome" hreflang="en">FDA greenlights Stealth Bio's injection as 1st treatment for Barth syndrome</a>](https://www.fiercebiotech.com/pharma/fda-greenlights-stealth-bios-injection-1st-treatment-barth-syndrome)**  
  _Sep 19, 2025 5:44pm_  
  After a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy for the condition.

- **[<a href="https://www.fiercebiotech.com/pharma/kennedys-acip-narrowly-avoids-vote-require-covid-19-vaccine-prescriptions" hreflang="en">RFK Jr.'s ACIP narrowly votes down recommendation for COVID-19 vaccine prescriptions</a>](https://www.fiercebiotech.com/pharma/kennedys-acip-narrowly-avoids-vote-require-covid-19-vaccine-prescriptions)**  
  _Sep 19, 2025 5:01pm_  
  In the second and final day of the CDC’s Advisory Committee on Immunization Practices September meeting, members of the panel scrapped one vote, reversed another and stopped just short of endorsing a third that had the potential to significantly impede COVID-19 vaccine access for many people living in the U.S.

- **[<a href="https://www.fiercebiotech.com/cro/one-third-data-collected-clinical-trials-may-be-unnecessary-study-finds" hreflang="en">One-third of data collected in clinical trials may be unnecessary, study finds</a>](https://www.fiercebiotech.com/cro/one-third-data-collected-clinical-trials-may-be-unnecessary-study-finds)**  
  _Sep 19, 2025 10:35am_  
  A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical data collection is translating into an increased burden on patients and trial sites.

- **[<a href="https://www.fiercebiotech.com/research/japan-biotech-inks-research-pact-efforts-develop-new-rna-meds" hreflang="en">Japan biotech inks research pact in effort to develop new RNA meds</a>](https://www.fiercebiotech.com/research/japan-biotech-inks-research-pact-efforts-develop-new-rna-meds)**  
  _Sep 19, 2025 10:21am_  
  Japan biotech xFOREST Therapeutics is teaming up with a drug discovery solutions provider in a research pact that aims to develop new RNA structure-targeted small molecule therapeutics, including mRNA candidates.

- **[<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-catalym-catalyzes-c-suite-shakeup" hreflang="en">Chutes &amp; Ladders—CatalYm catalyzes C-suite shake-up </a>](https://www.fiercebiotech.com/biotech/chutes-ladders-catalym-catalyzes-c-suite-shakeup)**  
  _Sep 18, 2025 5:13pm_  
  The German drug developer has tapped four industry leaders to take up spots in its C-suite, a move that has prompted three other executives to leave the company.

- **[<a href="https://www.fiercebiotech.com/biotech/carismas-lifeline-dissipates-reverse-merger-plans-fall-through-moderna-cuts-ties" hreflang="en">Carisma's lifeline dissipates as reverse merger plans fall through, Moderna cuts ties</a>](https://www.fiercebiotech.com/biotech/carismas-lifeline-dissipates-reverse-merger-plans-fall-through-moderna-cuts-ties)**  
  _Sep 18, 2025 10:41am_  
  After Carisma Therapeutics laid off 95% of its team earlier this year, a Hail Mary merger proposal with another biotech has fallen through.
